Pacira Biosciences, Inc. (PCRX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Vericel Corp.

Springworks Therapeutics, Inc.

Taro Pharmaceutical Industries Ltd.

Pacira Biosciences, Inc.

Ironwood Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

IDEAYA Biosciences, Inc.

CureVac NV

Supernus Pharmaceuticals, Inc.

PTC Therapeutics, Inc.

Biohaven Ltd.

Why is Pacira Biosciences, Inc. ?

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 3.20 times

With a growth in Operating Profit of 14.13%, the company declared Very Positive results in Jun 26

PRE-TAX PROFIT(Q) At USD 10.15 MM has Grown at 884.92%
INTEREST COVERAGE RATIO(Q) Highest at 915.41
RAW MATERIAL COST(Y) Fallen by -0.1% (YoY)

With ROCE of 3.40%, it has a attractive valuation with a 1.28 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -4.47%, its profits have fallen by -78.8%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Below par performance in long term as well as near term

Along with generating -4.47% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Pacira Biosciences, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Pacira Biosciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Pacira Biosciences, Inc.

-7.43%

-0.48

37.04%

S&P 500

20.6%

1.55

13.08%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.07%

EBIT Growth (5y)

-11.20%

EBIT to Interest (avg)

3.79

Debt to EBITDA (avg)

1.43

Net Debt to Equity (avg)

0.12

Sales to Capital Employed (avg)

0.53

Tax Ratio

52.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.06%

ROE (avg)

10.91%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.34

EV to EBIT

37.60

EV to EBITDA

8.96

EV to Capital Employed

1.28

EV to Sales

1.47

PEG Ratio

Dividend Yield

ROCE (Latest)

3.40%

ROE (Latest)

1.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

PRE-TAX PROFIT(Q)

At USD 10.15 MM has Grown at 884.92%

INTEREST COVERAGE RATIO(Q)

Highest at 915.41

RAW MATERIAL COST(Y)

Fallen by -0.1% (YoY

NET PROFIT(Q)

Highest at USD 12.25 MM

-4What is not working for the Company

NET PROFIT(9M)

At USD 13.29 MM has Grown at -34.28%

DEBTORS TURNOVER RATIO(HY)

Lowest at 6.03 times

Here's what is working for Pacira Biosciences, Inc.

Pre-Tax Profit

At USD 10.15 MM has Grown at 884.92%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 12.25 MM has Grown at 390.7%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Interest Coverage Ratio

Highest at 915.41

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Profit

Highest at USD 12.25 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost

Fallen by -0.1% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Pacira Biosciences, Inc.

Debtors Turnover Ratio

Lowest at 6.03 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio